Receptor agonists and antagonists and other modulators of purinergic signalling have potential as novel therapeutics for a broad range of diseases and conditions. This special issue focuses on compounds or approaches that are either in clinical trials or headed in that direction. It is intended to serve as an up-to-date description of selected efforts to discover and develop new small molecular purinergic drugs.
Keywords: ATP; Adenosine; Drug discovery; G protein-coupled purinergic receptors; Ligand-gated P2X receptors channels; Purinergic signalling.
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.